首页> 外文期刊>Journal of refractive surgery >Visual and refractive outcomes of LASIK with the SCHWIND ESIRIS and WaveLight ALLEGRETTO WAVE Eye-q excimer lasers: a prospective, contralateral study.
【24h】

Visual and refractive outcomes of LASIK with the SCHWIND ESIRIS and WaveLight ALLEGRETTO WAVE Eye-q excimer lasers: a prospective, contralateral study.

机译:SCHWIND ESIRIS和WaveLight ALLEGRETTO WAVE Eye-q准分子激光对LASIK的视觉和屈光结果:一项前瞻性对侧研究。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To compare the safety, efficacy, and predictability of LASIK with the SCHWIND ESIRIS and WaveLight ALLEGRETTO WAVE Eye-Q excimer laser platforms. METHODS: This prospective study comprised 44 eyes of 22 consecutive patients who were treated with LASIK using the Moria M2 microkeratome. One eye was treated with the SCHWIND ESIRIS laser and the fellow eye treated with the WaveLight ALLEGRETTO WAVE Eye-Q laser. All eyes operated with the SCHWIND ESIRIS were treated with standard aspheric ablation, whereas the eyes operated with the WaveLight ALLEGRETTO WAVE Eye-Q received treatment with three different ablation types according to the common practice at our clinic. Outcome measures were uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), manifest refraction, and proximity to target refraction at 6-month follow-up. RESULTS: At 6 months postoperative, mean decimal UCVA was 0.96+/-0.22 (range: 0.3 to 1.2) for ESIRIS eyes and 0.98+/-0.17 (range: 0.6 to 1.2) for ALLEGRETTO eyes (P=.57). Mean postoperative spherical equivalent refraction was -0.02+/-0.28 diopters (D) (range: -0.75 to +0.75 D) for ESIRIS eyes and 0.11+/-0.91 D (range: -1.00 to +3.88 D) for ALLEGRETTO eyes (P=.49). Of the ESIRIS eyes, 20/22 (91%) were within +/-1.00 D of target refraction and 20/22 (91%) were within +/-0.50 D of target refraction. Of the ALLEGRETTO eyes, 20/22 (91%) and 19/22 (86%) were within +/-1.00 D and +/-0.50 D, respectively, of target refraction. No patient lost > or =2 lines of BSCVA in either group. CONCLUSIONS: No differences were seen in safety and efficacy outcome parameters between the SCHWIND ESIRIS and WaveLight ALLEGRETTO WAVE Eye-Q excimer lasers when used according to a previously established treatment algorithm at our clinic in the treatment of refractive error.
机译:目的:为了比较LASIK与SCHWIND ESIRIS和WaveLight ALLEGRETTO WAVE Eye-Q准分子激光平台的安全性,有效性和可预测性。方法:这项前瞻性研究包括22例连续的患者的44只眼睛,这些患者使用Moria M2微型角膜刀术接受LASIK治疗。一只眼睛用SCHWIND ESIRIS激光治疗,另一只眼睛用WaveLight ALLEGRETTO WAVE Eye-Q激光治疗。 SCHWIND ESIRIS手术的所有眼睛均经过标准非球面消融治疗,而WaveLight ALLEGRETTO WAVE Eye-Q手术的眼睛根据我们诊所的常规做法接受了三种不同的消融治疗。结果指标是未矫正视力(UCVA),最佳眼镜矫正视力(BSCVA),明显屈光以及在6个月的随访中接近目标屈光。结果:术后6个月,ESIRIS眼平均十进制UCVA为0.96 +/- 0.22(范围:0.3至1.2),ALLEGRETTO眼平均UCVA为0.98 +/- 0.17(范围:0.6至1.2)(P = .57)。 ESIRIS眼的平均术后球面等效屈光度为-0.02 +/- 0.28屈光度(D)(范围:-0.75至+0.75 D)和ALLEGRETTO眼的平均屈光度为0.11 +/- 0.91 D(范围:-1.00至+3.88 D)( P = .49)。在ESIRIS眼中,20/22(91%)在目标屈光度的+/- 1.00 D以内,20/22(91%)在目标屈光度的+/- 0.5D的范围内。在ALLEGRETTO眼中,20/22(91%)和19/22(86%)分别在目标屈光度的+/- 1.00 D和+/- 0.50 D之内。两组均无患者丢失>或= 2行BSCVA。结论:根据我们诊所先前制定的治疗算法,SCHWIND ESIRIS和WaveLight ALLEGRETTO WAVE Eye-Q准分子激光在安全性和疗效结果参数上均未见差异。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号